5:52 PM
Nov 15, 2012
 |  BC Extra  |  Clinical News

Tranzyme plummets on Phase IIb miss for TZP-102

Shares of Tranzyme Inc. (NASDAQ:TZYM) plummeted $3.02 (76%) to $0.95 on Thursday after the company reported that once-daily 10 and 20 mg oral TZP-102 each missed the primary endpoint in a Phase IIb trial to treat diabetic gastroparesis. Specifically, low-...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >